Zacks Research Analysts Lower Earnings Estimates for Zoetis

Zoetis Inc. (NYSE:ZTS - Free Report) - Stock analysts at Zacks Research decreased their FY2025 earnings per share (EPS) estimates for Zoetis in a research note issued on Wednesday, January 8th. Zacks Research analyst E. Bagri now expects that the company will earn $6.36 per share for the year, down from their prior forecast of $6.37. The consensus estimate for Zoetis' current full-year earnings is $5.90 per share. Zacks Research also issued estimates for Zoetis' Q4 2025 earnings at $1.59 EPS, Q4 2026 earnings at $1.79 EPS and FY2026 earnings at $6.97 EPS.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the firm earned $1.36 EPS. The firm's quarterly revenue was up 11.6% compared to the same quarter last year.

A number of other research firms have also recently weighed in on ZTS. Leerink Partnrs raised Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Stifel Nicolaus reduced their price target on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research report on Tuesday. UBS Group assumed coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a "neutral" rating and a $196.00 price objective for the company. Finally, Leerink Partners started coverage on shares of Zoetis in a research report on Monday, December 2nd. They set an "outperform" rating and a $215.00 target price on the stock. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $211.89.

Zoetis Price Performance

Shares of NYSE ZTS traded down $1.72 during mid-day trading on Friday, hitting $163.30. 3,179,470 shares of the stock were exchanged, compared to its average volume of 2,470,128. The company has a market cap of $73.68 billion, a P/E ratio of 30.70, a PEG ratio of 2.91 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis has a twelve month low of $144.80 and a twelve month high of $200.53. The stock's fifty day simple moving average is $172.08 and its two-hundred day simple moving average is $180.20.

Institutional Trading of Zoetis

Several institutional investors and hedge funds have recently made changes to their positions in the business. Mizuho Securities USA LLC grew its stake in shares of Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company's stock worth $950,524,000 after purchasing an additional 4,829,815 shares during the period. International Assets Investment Management LLC grew its holdings in shares of Zoetis by 41,235.7% in the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company's stock valued at $183,652,000 after buying an additional 937,700 shares during the period. Marshall Wace LLP grew its holdings in shares of Zoetis by 7,608.6% in the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company's stock valued at $144,874,000 after buying an additional 824,843 shares during the period. Nordea Investment Management AB increased its position in shares of Zoetis by 38.3% in the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company's stock valued at $336,266,000 after buying an additional 572,511 shares in the last quarter. Finally, Holocene Advisors LP acquired a new stake in Zoetis during the 3rd quarter worth $110,809,000. Institutional investors own 92.80% of the company's stock.

Zoetis Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be paid a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This is a boost from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.22%. Zoetis's dividend payout ratio (DPR) is presently 37.59%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.